InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
5
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+57.2%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Ende Eric J, Director. Insider active across 2 companies, notably Matinas BioPharma Holdings, Inc.. Cumulatively, 8 reports have been recorded. Split: 5 buys · 0 sell. Total volume traded: €614k. Activity tracked since 19 June 2021. The latest transaction was disclosed on 13 January 2025 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations8 total
30,000 shares@ US$7.840637.4% of flowOrdinary SharesSEC:0001104659-25-003451:0
Ideal exit: 10 Oct 2025 (T+270)
11,000 shares0Ordinary SharesSEC:0001104659-24-084938:0
13,000 shares@ US$13.930827.4% of flowADSsSEC:0001104659-23-062694:0
Ideal exit: 12 Feb 2024 (T+270)
20,000 shares@ US$7.802524.8% of flowADSsSEC:0001104659-22-121721:0
Ideal exit: 19 Aug 2023 (T+270)
15,000 shares@ US$2.159646.8% of flowADSsSEC:0001104659-22-067241:0
Ideal exit: 25 Feb 2023 (T+270)
15,000 shares@ US$2.449853.2% of flowADSsSEC:0001104659-22-066222:0
Ideal exit: 21 Feb 2023 (T+270)
4,800 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000832
4,800 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000832:0
8 of 8 declarations
About Ende Eric J
Eric J. Ende is a Board Member at Matinas BioPharma Holdings, Inc. and AVADEL PHARMACEUTICALS PLC. He contributes to the company's strategy and important decision-making. His experience in the pharmaceutical sector is an asset for the company's future direction.
